vascular disease

Cooper Implants First Drug-Eluting Stent for PVD in New Jersey

Leave a Comment
Cooper Vascular Surgeons implanted the first drug eluting stent for the treatment of Peripheral Vascular Disease (PVD) in the State of New Jersey. Zilver® PTX®(COOK MEDICAL, Bloomington, IN), the first drug-eluting stent (DES) stent of its kind, was recently approved for use by the Food and Drug Administration (FDA) and made available to only a select few centers of excellence in the country.

Cooper Opens First Hybrid Operating Room in South Jersey to Treat Aortic Disease

2 Comments
Cooper University Hospital unveiled South Jersey’s first hybrid operating room yesterday. The $3 million suite combines state-of-the-art surgical technology with three-dimensional angiography where Cooper’s vascular and cardiothoracic surgeons can perform intricate, minimally-invasive endovascular surgery on patients with severe, life-threatening aortic conditions, 24 hours a day, seven days a week. Yesterday, doctors performed a successful endovascular repair of an abdominal aortic aneurysm in the new suite. “The hybrid OR places Cooper at the forefront of surgical technology and enables our surgeons to improve patient outcomes,” says Jeffrey P. Carpenter, M.D., Chief of Surgery at Cooper University Hospital. “The surgical suite has all the equipment, monitoring and imaging devices necessary to perform complex surgery without ever having to move the patient out of the OR during the procedure. This new technology is changing the standard of care in our region and Cooper is proud to be leading the way.”

Cooper University Hospital Named Primary Research Site for First and Only Global Clinical Trial for Endovascular Treatment of Type B Aortic Dissection

Leave a Comment
Cooper University Hospital will take part in a clinical trial of the first medical device designed to specifically treat aortic dissections, an often-fatal condition that affects tens of thousands in the U.S. and claimed the life of actor John Ritter. Recognized as a preferred treatment center for the minimally invasive treatment of aortic diseases, Cooper was approved by the hospital’s institutional review board (IRB) for its involvement in the study. This approval follows the recent appointment of the trial’s global principal investigator, Joseph V. Lombardi, M.D., FACS, as chief of vascular and endovascular surgery at Cooper and associate professor of surgery at the Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey.